Search - tctmd.com

Displaying 101 - 120 of 455

Sort: Relevancy | Date

News Conference News EuroPCR 2018

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

Yael L. Maxwell

May 30, 2018

News Daily News

One in Five ACS Patients Does Not Fill P2Y12 Inhibitor Prescription After PCI

Michael O'Riordan

May 21, 2018

News Conference News SCAI 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

Todd Neale

April 27, 2018

News Daily News

Another Observational Study Supports Role for Genotype-Guided Antiplatelet Choices Post-PCI

Yael L. Maxwell

April 04, 2018

News Conference News ACC 2018

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

Yael L. Maxwell

March 19, 2018

News Conference News ACC 2018

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Yael L. Maxwell

March 14, 2018

News Conference News ACC 2018

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

Yael L. Maxwell

March 12, 2018

News Conference News ACC 2018

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

Shelley Wood

March 11, 2018

News Conference News ACC 2018

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

Yael L. Maxwell

March 11, 2018

News Conference News ACC 2018

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

Caitlin E. Cox

March 11, 2018

News Conference News ACC 2018

ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More

Shelley Wood

March 11, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Acute MI Quality Improvement Program Fails in India, but Researchers See Bright Side

L.A. McKeown

February 15, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for January 2018

Shelley Wood

January 31, 2018

News Daily News

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

Yael L. Maxwell

January 04, 2018

News Daily News

Platelet Reactivity High in Most Patients Who Develop Stent Thrombosis

L.A. McKeown

December 20, 2017

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

Todd Neale

November 16, 2017

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Todd Neale

October 30, 2017

Advertisement

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

One in Five ACS Patients Does Not Fill P2Y12 Inhibitor Prescription After PCI

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

Another Observational Study Supports Role for Genotype-Guided Antiplatelet Choices Post-PCI

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

PHARMCLO: Biggest Genotyping Trial to Date Suggests Better Outcomes After ACS, With Caveats

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Acute MI Quality Improvement Program Fails in India, but Researchers See Bright Side

TCTMD’s Top 10 Most Popular Stories for January 2018

De-escalating DAPT to a Clopidogrel-Based Strategy After PCI for ACS Gets Boost in TOPIC-VASP

Platelet Reactivity High in Most Patients Who Develop Stent Thrombosis

RE-DUAL PCI Findings Consistent Across Key Subgroups

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content